- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Ryan Haumschild: What Health Systems Can Learn From Emory Healthcare's Biosimilar Strategy
Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, offers advice to health systems on how they can incorporate some of Emory Healthcare's strategies to promote biosimilar uptake.
Transcript
What strategies can health care institutions like Emory Healthcare implement to improve biosimilar adoption rates?
Haumschild: There are so many strategies, and it really depends on what's going on with your individual institution. I think a few of them are doing a baseline survey. You need to recognize where your barriers are because there are so many, but every institution is different. And so do we recognize is it related to the electronic medical record? Is it related to provider understanding and uptake? What about your finance team? Do they recognize that lower expense might recognize lower revenue, but that might not necessarily be a bad thing all the time?
I think when you can work through those barriers and designate key stakeholders to make more expedited decisions, that allows for faster uptake. Also, if you can get a P&T [pharmacy and therapeutics] policy approved, where pharmacy might have the ability to interchange biosimilars based on payer or individual hospital preferences, it allows for more timely adjudication and delivery of care to the patient and doing it at a reduced cost. So, I think if you can work through those barriers, focus on the electronic medical record, your key stakeholders clinically and financially, and create some of these tools, that's going to create better uptake, faster uptake, and you're going to be more efficient with your care model.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.
